In conclusion, the observed safety profile is considered favourable. Longer term safety data is awaitedfrom the ongoing clinical trials. There are very limited data on the use of the vaccine in immunocompromised individuals and on use in pregnancy and breastfeeding. No data was generated with mRNA-1273 when administered concomitantly with other vaccines. The CHMP considers … Continue reading COVID-19 Vaccine Assessment Report – Moderna European Medicines Agency